| 48.05 -0.45 (-0.93%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.8 | 1-year : | 68.68 |
| Resists | First : | 50.34 | Second : | 58.8 |
| Pivot price | 46.42  |
|||
| Supports | First : | 44.44 | Second : | 40.79 |
| MAs | MA(5) : | 48.44 |
MA(20) : | 45.47 |
| MA(100) : | 36.83 |
MA(250) : | 29.35 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 77.9 |
D(3) : | 82.7 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 50.34 | Low : | 19.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AGIO ] has closed below upper band by 32.6%. Bollinger Bands are 22.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.36 - 49.61 | 49.61 - 49.82 |
| Low: | 47.2 - 47.46 | 47.46 - 47.67 |
| Close: | 47.67 - 48.08 | 48.08 - 48.41 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
Leerink Partnrs Weighs in on Agios Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:AGIO) - MarketBeat
Fri, 26 Jul 2024
Agios Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.68) Per Share (NASDAQ:AGIO) - Defense World
Thu, 25 Jul 2024
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Thu, 25 Jul 2024
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Thu, 25 Jul 2024
ProShare Advisors LLC Has $407,000 Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Thu, 25 Jul 2024
Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Thursday - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 4.737e+007 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 4,470 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.8676e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 124.3 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 2.94e+007 % |
| Gross Profit (p.s.) | 58.97 |
| Sales Per Share | -50.79 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -301 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.6 |
| Price to Book value | 0 |
| Price to Sales | -0.95 |
| Price to Cash Flow | 2.85 |
| Dividend | 0 |
| Forward Dividend | 3.13e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|